Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines

Oncology Research

Volumn 16, Issue 4, 2006, Pages 179-193

  Pitfield, Sarah E ^a   Bryant, Ianthe ^a   Penington, Desi J ^a   Park, Gar ^a   Riese II, David J ^a  

^a Purdue University   (United States)

Author keywords

Breast cancer; ErbB4; Receptor tyrosine kinase; Signal transduction; Tumor suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; TYROSINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CELL; CANCER INHIBITION; CELL DEATH; CELL GROWTH; COLONY FORMATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

EID: 33750997293     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783981134     Document Type: Article

References (66)

1. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103:211-225; 2000.
2. Gullick, W. J. The type 1 growth factor receptors and their ligands considered as a complex system. Endocr. Relat. Cancer 8:75-82; 2001.
3. Stern, D. F. ErbBs in mammary development. Exp. Cell Res. 284:89-98; 2003.
4. Bazley, L. A.; Gullick, W. J. The epidermal growth factor receptor family. Endocr. Relat. Cancer 12(Suppl. 1):S17-27; 2005.
5. Bogdan, S.; Klambt, C. Epidermal growth factor receptor signaling. Curr. Biol. 11:R292-R295; 2001.
6. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212; 1990.
7. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-137; 2001.
8. Prenzel, N.; Fischer, O. M.; Streit, S.; Hart, S.; Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8:11-31; 2001.
9. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182; 1987.
10. Srinivasan, R.; Poulsom, R.; Hurst, H. C.; Gullick, W. J. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. 185:236-245; 1998.
11. Kew, T. Y.; Bell, J. A.; Finder, S. E.; Denley, H.; Srinivasan, R.; Gullick, W. J.; Nicholson, R. I.; Blamey, R. W.; Ellis, I. O. c-erbB-4 protein expression in human breast cancer. Br. J. Cancer 82:1163-1170; 2000.
12. Bacus, S. S.; Chin, D.; Yarden, Y.; Zelnick, C. R.; Stern, D. F. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am. J. Pathol. 148:549-558; 1996.
13. Srinivasan, R.; Gillett, C. E.; Barnes, D. M.; Gullick, W. J. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 60:1483-1487; 2000.
14. Witton, C. J.; Reeves, J. R.; Going, J. J.; Cooke, T. G.; Bartlett, J. M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200:290-297; 2003.
15. Tovey, S. M.; Witton, C. J.; Bartlett, J. M.; Stanton, P. D.; Reeves, J. R.; Cooke, T. G. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 6:R246-R251; 2004.
16. Knowlden, J. M.; Gee, J. M.; Seery, L. T.; Farrow, L.; Gullick, W. J.; Ellis, I. O.; Blarney, R. W.; Robertson, J. F.; Nicholson, R. I. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17:1949-1957; 1998.
17. Suo, Z.; Risberg, B.; Kalsson, M. G.; Willman, K.; Tierens, A.; Skovlund, E.; Nesland, J. M. EGFR family expression in breast carcinomas, c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol. 196:17-25; 2002.
18. Junttila, T. T.; Sundvall, M.; Lundin, M.; Lundin, J.; Tanner, M.; Harkonen, P.; Joensuu, H.; Isola, J.; Elenius, K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 65:1384-1393; 2005.
19. Peles, E.; Bacus, S. S.; Koski, R. A.; Lu, H. S.; Wen, D.; Ogden, S. G.; Levy, R. B.; Yarden, Y. Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205-216; 1992.
20. Tzahar, E.; Levkowitz, G.; Karunagaran, D.; Yi, L.; Peles, E.; Lavi, S.; Chang, D.; Liu, N.; Yayon, A.; Wen, D.; Yarden, Y. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J. Biol. Chem. 269:25226-25233; 1994.
21. Sartor, C. I.; Zhou, H.; Kozlowska, E.; Guttridge, K.; Kawata, E.; Caskey, L.; Harrelson, J.; Hynes, N.; Ethier, S.; Calvo, B.; Earp, 3rd, H. S. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol. Cell. Biol. 21:4265-4275; 2001.
22. Schroeder, J. A.; Lee, D. C. Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Differ. 9:451-464; 1998.
23. Jones, F. E.; Jerry, D. J.; Guarino, B. C.; Andrews, G. C.; Stern, D. F. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Cell Growth Differ. 7:1031-1038; 1996.
24. Jones, F. E.; Welte, T.; Fu, X. Y.; Stern, D. F. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J. Cell. Biol. 147:77-88; 1999.
25. Lodge, A. J.; Anderson, J. J.; Gullick, W. J.; Haugk, B.; Leonard, R. C.; Angus, B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J. Clin. Pathol. 56:300-304; 2003.
26. Bieche, I.; Onody, P.; Tozlu, S.; Driouch, K.; Vidaud, M.; Lidereau, R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int. J. Cancer 106:758-765; 2003.
27. Kainulainen, V.; Sundvall, M.; Maatta, J. A.; Santiestevan, E.; Klagsbrun, M.; Elenius, K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J. Biol. Chem. 275:8641-8649; 2000.
28. Määttä, J. A.; Sundvall, M.; Junttila, T. T.; Peri, L.; Laine, V. J. O.; Isola, J.; Egeblad, M.; Elenius, K. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol. Biol. Cell 17:67-79; 2006.
29. Tang, C. K.; Conception, X. Z.; Milan, M.; Gong, X.; Montgomery, E.; Lippman, M. E. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. 59:5315-5322; 1999.
30. Aguilar, Z.; Akita, R. W.; Finn, R. S.; Ramos, B. L.; Pegram, M. D.; Kabbinavar, F. F.; Pietras, R. J.; Pisacane, P.; Sliwkowski, M. X.; Slamon, D. J. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 18:6050-6062; 1999.
31. Riese, 2nd, D. J.; van Raaij, T. M.; Plowman, G. D.; Andrews, G. C.; Stern, D. F. The cellular response to neu-regulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol. 15:5770-5776; 1995.
32. Penington, D. J.; Bryant, I.; Riese, 2nd, D. J. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ. 13:247-256; 2002.
33. Williams, E. E.; Trout, L. J.; Gallo, R. M.; Pitfield, S. E.; Bryant, I.; Penington, D. J.; Riese, 2nd, D. J. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett. 192:67-74; 2003.
34. Leptak, C.; Ramon y Cajal, S.; Kulke, R.; Horwitz, B. H.; Riese, 2nd, D. J.; Dotto, G. P.: DiMaio, D. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J. Virol. 65:7078-7083; 1991.
35. Riese, 2nd, D. J.; DiMaio, D. An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. Oncogene 10:1431-1439; 1995.
36. Elenius, K.; Corfas, G.; Paul, S.; Choi, C. J.; Rio, C.; Plowman, G. D.; Klagsbrun, M. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J. Biol. Chem. 272:26761-26768; 1997.
37. Finlay, C. A.; Hinds, P. W.; Levine, A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093; 1989.
38. Baker, S. J.; Markowitz, S.; Fearon, E. R.; Willson, J. K.; Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915; 1990.
39. Riese, 2nd, D. J.; Komurasaki, T.; Plowman, G. D.; Stern, D. F. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J. Biol. Chem. 273:11288-11294; 1998.
40. Carraway, 3rd, K. L.; Cantley, L. C. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell 78:5-8; 1994.
41. Cohen, B. D.; Green, J. M.; Foy, L.; Fell, H. P. HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. J. Biol. Chem. 271:4813-4818; 1996.
42. Sweeney, C.; Carraway, 3rd, K. L. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 19:5568-5573; 2000.
43. Gozuacik, D.; Kimchi, A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891-2906; 2004.
44. Ni, C. Y.; Murphy, M. P.; Golde, T. E.; Carpenter, G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294:2179-2181; 2001.
45. Lee, H. J.; Jung, K. M.; Huang, Y. Z.; Bennett, L. B.; Lee, J. S.; Mei, L.; Kim, T. W. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J. Biol. Chem. 277:6318-6323; 2002.
46. Williams, C. C.; Allison, J. G.; Vidal, G. A.; Burow, M. E.; Beckman, B. S.; Marrero, L.; Jones, F. E. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J. Cell. Biol. 167:469-478; 2004.
47. Vidal, G. A.; Naresh, A.; Marrero, L.; Jones, F. E. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J. Biol. Chem. 280:19777-19783; 2005.
48. Yang, Z.; Barnes, C. J.; Kumar, R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin. Cancer Res. 10:3621-3628; 2004.
49. deFazio, A.; Chiew, Y. E.; Sini, R. L.; Janes, P. W.; Sutherland, R. L. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer 87:487-498; 2000.
50. Chittenden, T. BH3 domains: intracellular death-ligands critical for initiating apoptosis. Cancer Cell 2:165-166; 2002.
51. Chen, X.; Yeung, T. K.; Wang, Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem. Biophys. Res. Commun. 277:757-763; 2000.
52. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1:707-717; 2002.
53. Liang, K.; Jin, W.; Knuefermann, C.; Schmidt, M.; Mills, G. B.; Ang, K. K.; Milas, L.; Fan, Z. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol. Cancer Ther. 2:353-360; 2003.
54. Lesa, G. M.; Sternberg, P. W. Positive and negative tissue-specific signaling by a nematode epidermal growth factor receptor. Mol. Biol. Cell 8:779-793; 1997.
55. Dankort, D. L.; Wang, Z.; Blackmore, V.; Moran, M. F.; Muller, W. J. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol. Cell. Biol. 17:5410-5425; 1997.
56. Sweeney, C.; Lai, C.; Riese, 2nd, D. J.; Diamonti, A. J.; Cantley, L. C.; Carraway, 3rd, K. L. Ligand discrimination in signaling through an ErbB4 receptor homodimer. J. Biol. Chem. 275:19803-19807; 2000.
57. Burke, C. L.; Stern, D. F. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol. Cell Biol. 18:5371-5379; 1998.
58. Siegel, P. M.; Dankort, D. L.; Hardy, W. R.; Muller, W. J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell Biol. 14:7068-7077; 1994.
59. 1H NMR and circular dichroism study. Biochemistry 40:6534-6540; 2001.
60. Dawson, J. P.; Berger, M. B.; Lin, C.; Schlessinger, J.; Lemmon, M. A.; Ferguson, K. M. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol. Cell Biol. 25:7734-7742; 2005.
61. Saito, T.; Okada, S.; Ohshitna, K.; Yamada, E.; Sato, M.; Uehara, Y.; Shimizu, H.; Pessin, J. E.; Mori, M. Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF. Endocrinology 145:4232-4243; 2004.
62. Sweeney, C.; Lai, C.; Riese, D. J.; Diamonte, A. J.; Cantley, L. C.; Carraway, K. L. Ligand discrimination in signaling through an ErbB4 receptor homodimer. J. Biol. Chem. 275:19803-19807; 2000.
63. Hobbs, S. S.; Coffing, S. L.; Le, A. T. D.; Cameron, E. M.; Williams, E. E.; Andrew, M.; Blommel, E. N.; Hammer, R. P.; Chang, H.; Riese, D. J. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 21:8442-8452; 2002.
64. Hobbs, S. S.; Cameron, E. M.; Hammer, R. P.; Le, A. T. D.; Gallo, R. M.; Blommel, E. N.; Coffing, S. L.; Chang, H.; Riese, D. J. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 23:883-893; 2004.
65. Amin, D. N.; Perkins, A. S.; Stern, D. F. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene 23:1428-1438; 2004.
66. Weinstein, E. J.; Grimm, S.; Leder, P. The oncogene heregulin induces apoptosis in breast epithelial cells and tumors. Oncogene 17:2107-2113; 1998.